- Home
- REXR vs PRAX Comparison
REXR vs PRAX Comparison
Compare REXR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REXR | PRAX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | REXR | PRAX |
|---|---|---|
| Price | $37.66 | $335.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $42.10 | ★ $560.80 |
| AVG Volume (30 Days) | ★ 2.6M | 436.3K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | $3.73 | $38,343.63 |
| P/E Ratio | $43.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.68 | $26.70 |
| 52 Week High | $44.38 | $349.32 |
Technical Indicators
Market Signals| Indicator | REXR | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 60.59 |
| Support Level | $36.32 | $293.01 |
| Resistance Level | $37.79 | $334.61 |
| Average True Range (ATR) | 0.91 | 18.25 |
| MACD | -0.21 | -0.31 |
| Stochastic Oscillator | 10.80 | 88.00 |
Price Performance
Historical ComparisonAbout REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.